Velcera, Inc.

Velcera, Inc. specializes in developing innovative veterinary pharmaceuticals that enhance pet health and wellbeing. The company focuses on creating effective treatment solutions for common pet ailments, improving the quality of life for animals. Velcera, Inc.

is a company that develops veterinary pharmaceuticals aimed at improving pet health. In February 2013, it was acquired by Perrigo Company Plc for USD 160. 00 mn, marking a significant strategic move for the company. Velcera is headquartered in the US and has been involved in three different deals to date.

Velcera offers a range of veterinary pharmaceutical products designed to treat various conditions in pets. Their product lineup includes treatments for common ailments affecting dogs and cats, ensuring pet owners have access to effective medical solutions. The company aims to support veterinarians and pet owners in maintaining animal wellbeing through high-quality pharmaceutical offerings. Velcera's revenue is primarily derived from sales of its veterinary pharmaceutical products, which are structured to meet the needs of pet owners and veterinarians.

The company operates on a direct-to-consumer model, providing its products through veterinary clinics and online channels, enhancing accessibility for customers. Velcera's future growth strategy involves expanding its product portfolio by developing new veterinary therapeutic solutions aimed at common pet health issues. The company aims to penetrate additional markets by the end of 2024, focusing on regions with increasing pet ownership and demand for quality pet healthcare. The recent acquisition funding of USD 160.

00 mn by Perrigo Company will support these initiatives, allowing Velcera to enhance its research and development capabilities.